2023
Long-term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children With Neurogenic Detrusor Overactivity
Franco I, Hoebeke P, Dobremez E, Titanji W, Geib T, Jenkins B, Yushmanova I, Austin P. Long-term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children With Neurogenic Detrusor Overactivity. Journal Of Urology 2023, 209: 774-784. PMID: 36655470, DOI: 10.1097/ju.0000000000003157.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsNeurogenic detrusor overactivityUrinary tract infectionAdverse eventsSingle-treatment studyDetrusor overactivityTract infectionsSafety profileCommon treatment-emergent adverse eventsSerious treatment-emergent adverse eventsUrinary tract infection rateSimilar safety profileClean intermittent catheterizationNew safety concernsLong-term safetyAutonomic dysreflexiaIntermittent catheterizationMedian durationOnabotulinumtoxinA treatmentDistant spreadDose groupPediatric dataRepeat treatmentRepeated TreatmentPatients
2022
Long-Term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children with Neurogenic Detrusor Overactivity
Franco I, Dobremez E, Hoebeke P, Titanji W, Yushmanova I, Jenkins B, Austin P. Long-Term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children with Neurogenic Detrusor Overactivity. Toxicon 2022, 214: s18-s19. DOI: 10.1016/j.toxicon.2021.11.049.Peer-Reviewed Original Research
2021
P1063 Long-term safety and tolerability of repeated treatments with onabotulinumtoxinA in children with neurogenic detrusor overactivity
Franco I, Dobremez E, Hoebeke P, Titanji W, Yushmanova I, Jenkins B, Austin P. P1063 Long-term safety and tolerability of repeated treatments with onabotulinumtoxinA in children with neurogenic detrusor overactivity. European Urology 2021, 79: s1506-s1507. DOI: 10.1016/s0302-2838(21)01435-4.Peer-Reviewed Original ResearchEfficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial
Austin P, Franco I, Dobremez E, Kroll P, Titanji W, Geib T, Jenkins B, Hoebeke P. Efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial. Toxicon 2021, 190: s6. DOI: 10.1016/j.toxicon.2020.11.352.Peer-Reviewed Original Research
2020
751 Efficacy and safety of three active doses of onabotulinum toxin A for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial
Hoebeke P, Austin P, Franco I, Dobremez E, Kroll P, Titanji W, Geib T, Jenkins B. 751 Efficacy and safety of three active doses of onabotulinum toxin A for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial. European Urology Open Science 2020, 19: e1147. DOI: 10.1016/s2666-1683(20)33351-6.Peer-Reviewed Original Research